SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-21-011562
Filing Date
2021-08-13
Accepted
2021-08-13 07:01:31
Documents
59
Period of Report
2021-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q tril-20210630x10q.htm   iXBRL 10-Q 1430179
2 EX-31.1 tril-20210630xex31d1.htm EX-31.1 13240
3 EX-31.2 tril-20210630xex31d2.htm EX-31.2 13266
4 EX-32.1 tril-20210630xex32d1.htm EX-32.1 10258
5 GRAPHIC tril-20210630x10q008.jpg GRAPHIC 92893
  Complete submission text file 0001558370-21-011562.txt   5328815

Data Files

Seq Description Document Type Size
6 EX-101.SCH tril-20210630.xsd EX-101.SCH 39355
7 EX-101.CAL tril-20210630_cal.xml EX-101.CAL 41026
8 EX-101.DEF tril-20210630_def.xml EX-101.DEF 157416
9 EX-101.LAB tril-20210630_lab.xml EX-101.LAB 376194
10 EX-101.PRE tril-20210630_pre.xml EX-101.PRE 287041
11 EXTRACTED XBRL INSTANCE DOCUMENT tril-20210630x10q_htm.xml XML 665359
Mailing Address 2488 DUNWIN DRIVE MISSISSAUGA A6 L5L 1J9
Business Address 2488 DUNWIN DRIVE MISSISSAUGA A6 L5L 1J9 (416) 595-0627
Trillium Therapeutics Inc. (Filer) CIK: 0001616212 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36596 | Film No.: 211169683
SIC: 2834 Pharmaceutical Preparations